Kirby sells CMRX 42.74: On average, analysts expect Chimerix to post $-2.41 EPS for the current fiscal year and $-2.22 EPS for the next fiscal year.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Monday, May 11th. Analysts expect the company to announce earnings of ($0.59) per share and revenue of $1.37 million for the quarter. Demski sold 2,000 shares of Chimerix stock in a transaction on Wednesday, July 1st. Trost sold 28,000 shares of Chimerix stock in a transaction on Friday, July 17th. Equities research analysts expect that Chimerix will post ($2.41) earnings per share for the current year.


Sachiko:
Results showed a mortality rate of less than 40 percent for bone marrow transplant recipients with disseminated adenovirus disease and for the patient population.

Tamesha:
Earlier this year, Chimerix reported preliminary results from the initial 85 patients enrolled in AdVise and treated with brincidofovir.

Jeannie:
It began enrolling in March 2014. With no approved treatment for adenovirus, short-term mortality rates have been reported as high as 80 percent in patients with disseminated disease, according to Chimerix.

Shela:
As recently as April 30, shares traded at $34, but climbed to $55.72 Monday, an all-time high and a 64 percent increase in just about three months.

Scarlet:
Michelle Berrey, CEO of Chimerix.

Tifany:
The Phase 3 AdVise trial began enrolling in March 2014. Patients with confirmed adenovirus infection receive brincidofovir orally twice-weekly for 12 weeks, and are followed for a minimum of 12 weeks after treatment.

Blanch:
Grimley, MD, Associate Professor of Clinical Pediatrics, Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, and lead investigator for AdVise.

Selma:
There is no approved antiviral treatment for adenovirus infection.

Alycia:
Demski sold 2,000 shares of the stock in a transaction that occurred on Wednesday, July 1st.

Penelope:
In other Chimerix news, CFO Timothy W.

Chimerix Inc. (NASDAQ:CMRX)
//stockhand.net/us/?q=nasdaq%3Acmrx&id=225369